NantHealth’s Cancer Therapy Pre-Authorization Platform Eviti Connect® Starts 2020 Strong with Two Expanded Programs
February 27 2020 - 8:00AM
Business Wire
Continued Relationships with Health Insurers
Reflect the Need for High-quality, High-value Care as Cancer
Treatments Become Increasingly Complex
NantHealth, Inc. (NASDAQ: NH), a next-generation,
evidence-based, personalized healthcare company, announced today
two expanded programs with Eviti Connect®, NantHealth’s healthcare
payer solution and provider decision support software. A leading
U.S. Medicaid health plan expanded its coverage and one of the
largest non-profit, rural health plans in the country offering
coverage for 165,000 members will continue to drive high-value
oncological care with Eviti Connect.
Eviti Connect streamlined the pre-authorization process for
cancer treatments and reduced denials and appeals for this leading
U.S. Medicaid health plan, while providing oncologists in their
network with access to a comprehensive library of evidence-based
treatment options for optimal decision making. For one of the
largest non-profit rural health plans in the country, Eviti Connect
improved consistency in the use of evidence-based medicine,
simplified processes, and streamlined treatment approvals that
enable cancer patients to begin treatment quickly and
efficiently.
“Implementation of the Affordable Care Act has resulted in a
much more diverse Medicaid population,” said Dr. William Flood,
Chief Medical Officer for Eviti at NantHealth. “Medicaid plans now
must address more members and a higher prevalence of cancer.
Eviti’s comprehensive evidence-based medical library and
experienced oncology medical staff enables Medicaid programs to
evolve and meet these new challenges quickly.”
The Medicaid health plan experienced compelling results in their
two-state pilot program. During the two-year pilot, which covered
approximately 250,000 members, the insurer noted a significant
improvement in the use of evidence-based medicine for member
oncology care as a result of providers submitting treatment
requests via Eviti Connect. The successful pilot led the insurer to
expand the program from two to 10 U.S. states.
For Eviti Connect to continue to help assure quality, high-value
care for members with cancer, the non-profit, rural health plan
signed a three-year renewal agreement. Under terms of the
agreement, the health plan’s provider network will continue to
benefit from Eviti Connect decision support solution, which
includes evidence-based treatment regimens, condition-specific
clinical trial options, and the potential for more efficient
preauthorization and expedited reimbursement.
“This renewal of Eviti Connect by a large health plan
demonstrates our continued leadership in delivering solutions that
align the priorities of physicians, patients, and payers at the
moment of clinical prescribing to promote the best care for
patients,” said Mark Mozley, Senior Vice President, Global Sales
& Marketing, NantHealth. “We are pleased to continue this
relationship momentum and support our clients’ goals to exceed
industry standards for the authorization of oncology care.”
NantHealth’s Eviti Connect is a web-based healthcare payer
solution that electronically connects health plans and oncology
practices for the authorization of treatment plans in near
real-time. Eviti Connect reduces the administrative time involved
in obtaining authorizations at the drug level, assures appropriate
reimbursement at the regimen level, and validates cancer treatment
options overall. It also provides the ability to have peer-to-peer
conversations between prescribing oncologists and NantHealth
oncologists.
About NantHealth, Inc.
NantHealth, a member of the NantWorks ecosystem of companies,
provides leading solutions across the continuum of care for
physicians, payers, patients and biopharmaceutical organizations.
NantHealth enables the use of cutting-edge data and technology
toward the goals of empowering clinical decision support and
improving patient outcomes. NantHealth’s comprehensive product
portfolio combines the latest technology in payer/provider
platforms that exchange information in near-real time (NaviNet and
Eviti), and molecular profiling services that combine comprehensive
DNA & RNA tumor-normal profiling with pharmacogenomics analysis
(GPS Cancer®). For more information, please visit nanthealth.com or
follow us on Twitter, Facebook and LinkedIn.
This news release contains certain statements of a
forward-looking nature relating to future events or future business
performance. Forward-looking statements can be identified by the
words “expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Risks and uncertainties include, but are not limited to: our
ability to successfully integrate a complex learning system to
address a wide range of healthcare issues; our ability to
successfully amass the requisite data to achieve maximum network
effects; appropriately allocating financial and human resources
across a broad array of product and service offerings; raising
additional capital as necessary to fund our operations; achieving
significant commercial market acceptance for our sequencing and
molecular analysis solutions; establish relationships with key
thought leaders or payers’ key decision makers in order to
establish our sequencing and molecular analysis solutions as a
standard of care for patients with cancer; our ability to grow the
market for our systems infrastructure and applications;
successfully enhancing our systems infrastructure and applications
to achieve market acceptance and keep pace with technological
developments; customer concentration; competition; security
breaches; bandwidth limitations; our ability to continue our
relationship with NantOmics; our ability to obtain regulatory
approvals; dependence upon senior management; the need to comply
with and meet applicable laws and regulations; unexpected adverse
events; clinical adoption and market acceptance of our sequencing
and molecular analysis solutions; and anticipated cost savings. We
undertake no obligation to update any forward-looking statement in
light of new information or future events, except as otherwise
required by law. Forward-looking statements involve inherent risks
and uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, many of which are
discussed in more detail in our reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200227005286/en/
NantHealth Jen Hodson Jen@nant.com 562-397-3639
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Aug 2024 to Sep 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Sep 2023 to Sep 2024